Molecular therapy in urologic oncology. - Wikidata - awgldk - TriplyDB

Molecular therapy in urologic oncology.

Molecular therapy in urologic oncology.

http://www.wikidata.org/entity/Q36878961

about

Molecular markers in prostate cancer. Part II: potential roles in management.Significance of serum tumor necrosis factor-related apoptosis-inducing ligand as a prognostic biomarker for renal cell carcinoma.

P2860

Q37339702-0915D787-0318-4C5F-BA2A-705B8456649B Q38292479-79E5FC73-874F-499E-8C29-341B3A80E9AC

P2860

Molecular therapy in urologic oncology.

http://www.wikidata.org/entity/Q36878961

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Molecular therapy in urologic oncology.

@en

type

label

Molecular therapy in urologic oncology.

@en

prefLabel

Molecular therapy in urologic oncology.

@en

P1433

Q36878961-E41DDA17-1A20-460C-AE42-6CE1325AC8F0

P1476

Q36878961-031515D9-BC8D-4670-9989-438C2FDBEEAC

P2093

Q36878961-64BA43D1-EBD3-4924-A8DE-031336F4166A

Q36878961-CB1B824B-4C7E-4D44-B999-BADF02FFE65D

Q36878961-EE5E720C-20EE-4309-AD15-394667B88EEE

P2860

Q36878961-18408F81-6F9A-41ED-94C3-D6E186239260

Q36878961-1C0D7A11-A8EB-491C-A06A-DBABA1BEC8EA

Q36878961-2B4598C5-D0A9-47EA-8F5E-52D1A16084F9

Q36878961-3BD7E4F3-15A7-413B-A89E-021179639E51

Q36878961-406EDCBD-8276-4CF0-8CB4-4C9EE852686F

Q36878961-4401B9C4-18F8-4165-A040-9D93DE11BAD6

Q36878961-4C15CEAA-2BDA-43F3-9D0B-2191BB68B49C

Q36878961-50E1F963-0707-43C4-B984-56C21E391366

Q36878961-519B25CB-4469-4072-9F91-090665837F48

Q36878961-5CD8358C-F6D5-47A1-B7E0-CEFF14A6F8B8

P304

Q36878961-37A3F3DA-87EC-4730-BBF1-914422FBD69F

P31

Q36878961-2E85BDC6-69D2-4ED9-A66D-6109EA123989

P356

Q36878961-CFE788E1-948D-4B15-A92B-2413E20EFEB6

P433

Q36878961-AEC9F47D-0AC6-49DF-8FF3-F4C2426AB518

P478

Q36878961-3104642C-E531-4DDC-8288-B08C59FAE26A

P577

Q36878961-760347DB-F8A1-4CBF-B483-AD5F2463B66B

P698

Q36878961-D3A27808-D432-4D90-B6C5-EC537AADE312

P356

P1433

Urologia internationalis

P1476

Molecular therapy in urologic oncology.

@en

P2093

Manfred P Wirth

http://www.w3.org/2001/XMLSchema#string

Michael Froehner

http://www.w3.org/2001/XMLSchema#string

Oliver W Hakenberg

http://www.w3.org/2001/XMLSchema#string

P2860

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Sorafenib in advanced clear-cell renal-cell carcinoma

Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.

Role of tyrosine kinase inhibitors in cancer therapy.

Kinase inhibitors in the treatment of renal cell carcinoma.

Targeted therapy for metastatic renal cell carcinoma.

KIT mutations are common in testicular seminomas.

Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma.

Emerging treatment strategies for adrenocortical carcinoma: a new hope.

P304

1-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000102904

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

79

http://www.w3.org/2001/XMLSchema#string

P577

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17627159

http://www.w3.org/2001/XMLSchema#string